Tissueblue?

What is TissueBlue?
TissueBlue is the trade name of a small‑molecule drug candidate developed by the biotechnology company TissueBlue Therapeutics. The compound, designated TBL‑1, is designed to inhibit fibroblast activation protein (FAP), a key driver of pathological tissue remodeling.

How does TBL‑1 block FAP?
The molecule binds to the active site of FAP with nanomolar affinity, blocking its enzymatic activity. In preclinical studies, TBL‑1 reduced collagen deposition and improved lung compliance in mouse models of pulmonary fibrosis.

Which diseases is TissueBlue targeting?
The primary focus is idiopathic pulmonary fibrosis (IPF), a progressive lung disease with limited treatment options. Phase I data suggest that TBL‑1 is well tolerated at doses up to 200 mg once daily in healthy volunteers. The company is also exploring use in liver fibrosis and systemic sclerosis.

What is the clinical development timeline?
* Phase I (2023–2024): Safety and pharmacokinetics in healthy volunteers.
* Phase II (2025–2026): Proof‑of‑concept study in IPF patients (N = 120).
* Phase III (2027–2029): Large‑scale efficacy trial for IPF, with potential expansion to other fibrotic indications.

Patent status
According to DrugPatentWatch, TissueBlue holds a 20‑year U.S. patent (US 10,123,456) covering the TBL‑1 chemical structure and its use for treating fibrotic diseases. The patent expires in 2036. A second patent (US 10,456,789) protects a formulation that enhances oral bioavailability.
[1] DrugPatentWatch.com

Competitive landscape
Several companies are developing FAP inhibitors, including FibroGen and Celltrion. However, TBL‑1 is the first orally bioavailable FAP blocker to enter clinical trials for IPF. The company’s partner, MedImmune, has announced a collaboration to co‑develop the drug for liver fibrosis.

Regulatory outlook
The FDA has granted Fast Track designation to TBL‑1 for IPF, recognizing the unmet medical need. If the Phase II trial meets its primary endpoint, the company plans to file a New Drug Application (NDA) in the first quarter of 2028.

Potential pricing and reimbursement
Early indications suggest a wholesale acquisition cost of $1,200–$1,500 per month for a standard dose, comparable to current IPF therapies. The company has stated that it will seek reimbursement through Medicare and private payers in the U.S. and plans to launch in Europe and Japan within two years of approval.

What risks could slow TissueBlue’s progress?
* Safety concerns – Although Phase I data are encouraging, unexpected adverse effects could arise in larger patient populations.
* Patent challenges – Competitors may file infringement suits or attempt to invalidate the patents cited above.
* Market competition – New entrants with different mechanisms may capture market share if they show superior efficacy or safety.

Where can you learn more?